Is an HIV vaccine possible?

Nature Medicine

Volumn 5, Issue 6, 1999, Pages 612-614

  McMichael, Andrew J ^a   Hanke, Tomas ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; DNA; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; TUMOR NECROSIS FACTOR;

CELLULAR IMMUNITY; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SHORT SURVEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; VIRUS ENVELOPE;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

HUMAN IMMUNODEFICIENCY VIRUS; MACACA; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0033040191     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/9455     Document Type: Short Survey

References (21)

1. Poignard, P. et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infections in vivo. Immunity 10, 431-438 (1999).
2. Berman, P. et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345, 622-625 (1990).
3. Connor, R.I. et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72, 1552-1576 (1998).
4. Wyatt, R. et al. The antigenic structure of the HIV gp120 envelope glycoprotein [see comments]. Nature 393, 705-711 (1998).
5. Schneider, J. et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med. 4, 397-402 (1998).
6. Borrow, P., Lewicki, H., Hahn, B.H., Shaw, G.M. & Oldstone, M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol 68, 6103-6110 (1994).
7. McMichael, A. T cell responses and viral escape. Cell 93, 673-676 (1998).
8. Rowland-Jones, S.L. et al. Cytotoxic T-cell responses to multiple conserved epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102, 1758-1765 (1998).
9. Paxton, W.A. et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nature Med. 2, 412-417 (1996).
10. Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K. & Desrosiers, R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938-1941 (1992).
11. Almond, N. et al. Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. J. Gen. Virol. 78, 1919-1922 (1997).
12. Stebbings, R. et al. Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection. AIDS Res. Hum. Retroviruses 14, 1187-1198 (1998).
13. Hu, S.-L. et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255, 255-459 (1992).
14. Gallimore, A. et al. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nature Med. 1, 1167-1173 (1995).
15. Boyer, J. et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med. 3, 526-532 (1997).
16. Lehner, T. et al. Protective mucosal immunity elicited by targeted iliac lymph node immunisation with a subunit SIV envelope and core vaccine in macaques. Nature Med. 2, 767-775 (1996).
17. Letvin, N. et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Natl. Acad. Sci. USA 94, 9378-9383 (1997).
18. Robinson, H.L. et al. Neutralizing anitbody independent containment of immunnodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nature Med. 5, 525-534 (1999).
19. Kent, S. et al. Enhanced T-Cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72, 10180-10188 (1998).
20. Cafaro, A. et al. Control of SHIV-89.6P infection of cynomolgus monkeys by HIV-1 tat protein vaccine. Nature Med. 5, 643-650 (1999).
21. McMichael, A.J. & O'Callaghan, C.A. A new look at T cells. J. Exp. Med. 187, 1367-1371 (1998).